Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacoby, R. F.
Right arrow Articles by Lubet, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacoby, R. F.
Right arrow Articles by Lubet, R. A.
[Cancer Research 60, 5040-5044, September 15, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Preventive and Therapeutic Agent in the Min Mouse Model of Adenomatous Polyposis1

Russell F. Jacoby2, Karen Seibert, Carolyn E. Cole, Gary Kelloff and Ronald A. Lubet

University of Wisconsin Comprehensive Cancer Center [R. F. J., C. E. C.] and Department of Medicine, Section of Gastroenterology [R. F. J.], University of Wisconsin, Madison, Wisconsin 53792; Searle Research and Development, St. Louis, Missouri 63167 [K. S.]; and Chemoprevention Branch, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892 [G. K., R. A. L.]

Epidemiological and animal studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce colon cancer risk. NSAIDs nonselectively inhibit both the constitutive cyclooxygenase (COX) 1 associated with side effects and the desired therapeutic target COX-2, which is induced in inflammation and neoplasia. We used the adenomatous polyposis coli (Apc) mutant Min mouse model to determine whether the selective COX-2 inhibitor celecoxib is effective for adenoma prevention and/or regression, and whether it might be safer than the nonselective NSAID previously shown to be most effective in this model, piroxicam. Min mice (n = 120) were randomized to treatment with celecoxib (0, 150, 500, or 1500 ppm celecoxib mixed in the diet) or piroxicam. To distinguish prevention from regression effects, groups were treated either "early" (before adenomas develop) or "late" (after most adenomas are established). Celecoxib caused dramatic reductions in both the multiplicity and size of tumors in a dose-dependent manner (P < 0.01). Early treatment with 1500 ppm of celecoxib was effective for prevention, decreasing tumor multiplicity to 29% and tumor size to only 17% of controls (P < 0.01). Late treatment demonstrated regression effects, reducing tumor multiplicity and size by about half. In contrast to the significant toxicity of piroxicam, which caused ulcers complicated by perforation and bleeding, celecoxib caused no gastrointestinal side effects and did not inhibit platelet thromboxane B2 at plasma drug levels similar to those obtained in early clinical trials in humans. These results provide the first evidence that selective inhibitors of COX-2 are safe and effective for the prevention and regression of adenomas in a mouse model of adenomatous polyposis and strongly support ongoing clinical trials in humans with the same syndrome. The broader population of patients with common sporadic adenomas that have somatic mutations of the same gene (APC) may also benefit from this treatment approach.




This article has been cited by other articles:


Home page
 Ann OncolHome page
C.-H. Kohne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Muller, J. Janssens, et al.
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015
Ann. Onc., May 1, 2008; 19(5): 920 - 926.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Korsisaari, I. M. Kasman, W. F. Forrest, N. Pal, W. Bai, G. Fuh, F. V. Peale, R. Smits, and N. Ferrara
From the Cover: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice
PNAS, June 19, 2007; 104(25): 10625 - 10630.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. M. Amos-Landgraf, L. N. Kwong, C. M. Kendziorski, M. Reichelderfer, J. Torrealba, J. Weichert, J. D. Haag, K.-S. Chen, J. L. Waller, M. N. Gould, et al.
A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer
PNAS, March 6, 2007; 104(10): 4036 - 4041.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. Hawk and J. L. Viner
The Adenoma Prevention with Celecoxib and Prevention of Colorectal Sporadic Adenomatous Polyps Trials: Stepping Stones to Progress
Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 185 - 187.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. Schottenfeld and J. Beebe-Dimmer
Alleviating the Burden of Cancer: A Perspective on Advances, Challenges, and Future Directions.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2049 - 2055.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
R. D. Cardiff, M. R. Anver, G. P. Boivin, M. W. Bosenberg, R. R. Maronpot, A. A. Molinolo, A. Y. Nikitin, J. E. Rehg, G. V. Thomas, R. G. Russell, et al.
Precancer in Mice: Animal Models Used to Understand, Prevent, and Treat Human Precancers
Toxicol Pathol, October 1, 2006; 34(6): 699 - 707.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. Lou, N. Fatima, Z. Xiao, S. Stauffer, G. Smythers, P. Greenwald, and I. U. Ali
Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1598 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. L. Eisinger, L. D. Nadauld, D. N. Shelton, P. W. Peterson, R. A. Phelps, S. Chidester, D. M. Stafforini, S. M. Prescott, and D. A. Jones
The Adenomatous Polyposis Coli Tumor Suppressor Gene Regulates Expression of Cyclooxygenase-2 by a Mechanism That Involves Retinoic Acid
J. Biol. Chem., July 21, 2006; 281(29): 20474 - 20482.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. M. Carothers, A. E. Moran, N. L. Cho, M. Redston, and M. M. Bertagnolli
Changes in Antitumor Response in C57BL/6J-Min/+ Mice during Long-term Administration of a Selective Cyclooxygenase-2 Inhibitor.
Cancer Res., June 15, 2006; 66(12): 6432 - 6438.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Reddy, C. X. Wang, A.-N. Kong, T. O. Khor, X. Zheng, V. E. Steele, L. Kopelovich, and C. V. Rao
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in f 344 rats.
Cancer Res., April 15, 2006; 66(8): 4542 - 4546.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M.A. Hull, O.O. Faluyi, C.W.S. Ko, S. Holwell, D.J. Scott, R.J. Cuthbert, R. Poulsom, R. Goodlad, C. Bonifer, A.F. Markham, et al.
Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis
Carcinogenesis, March 1, 2006; 27(3): 382 - 391.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. D'Orazi, M. G. Sciulli, V. Di Stefano, S. Riccioni, M. Frattini, R. Falcioni, L. Bertario, A. Sacchi, and P. Patrignani
Homeodomain-Interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2-Dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells
Clin. Cancer Res., February 1, 2006; 12(3): 735 - 741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Martin, D. C. Phillips, K. Szekely-Szucs, L. Elghazi, F. Desmots, and J. A. Houghton
Cyclooxygenase-2 Inhibition Sensitizes Human Colon Carcinoma Cells to TRAIL-Induced Apoptosis through Clustering of DR5 and Concentrating Death-Inducing Signaling Complex Components into Ceramide-Enriched Caveolae
Cancer Res., December 15, 2005; 65(24): 11447 - 11458.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss
Inflammation and Endometrial Cancer: A Hypothesis
Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2840 - 2847.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H A Patsos, D J Hicks, R R H Dobson, A Greenhough, N Woodman, J D Lane, A C Williams, and C Paraskeva
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2
Gut, December 1, 2005; 54(12): 1741 - 1750.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Gasparini, D. Gattuso, A. Morabito, R. Longo, F. Torino, R. Sarmiento, S. Vitale, T. Gamucci, and L. Mariani
Combined Therapy with Weekly Irinotecan, Infusional 5-Fluorouracil and the Selective COX-2 Inhibitor Rofecoxib Is a Safe and Effective Second-Line Treatment in Metastatic Colorectal Cancer
Oncologist, October 1, 2005; 10(9): 710 - 717.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Reddy, J. M. Patlolla, B. Simi, S.H. Wang, and C. V. Rao
Prevention of Colon Cancer by Low Doses of Celecoxib, a Cyclooxygenase Inhibitor, Administered in Diet Rich in {omega}-3 Polyunsaturated Fatty Acids
Cancer Res., September 1, 2005; 65(17): 8022 - 8027.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Cai, M. Al-Fayez, R. G. Tunstall, S. Platton, P. Greaves, W. P. Steward, and A. J. Gescher
The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice
Mol. Cancer Ther., September 1, 2005; 4(9): 1287 - 1292.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Shao, C. Jung, C. Liu, and H. Sheng
Prostaglandin E2 Stimulates the {beta}-Catenin/T Cell Factor-dependent Transcription in Colon Cancer
J. Biol. Chem., July 15, 2005; 280(28): 26565 - 26572.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. K. Roy, Y. L. Kim, R. K. Wali, Y. Liu, J. Koetsier, D. P. Kunte, M. J. Goldberg, and V. Backman
Spectral Markers in Preneoplastic Intestinal Mucosa: An Accurate Predictor of Tumor Risk in the MIN Mouse
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1639 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Fux, M. Schwab, K.-P. Thon, C. H. Gleiter, and P. Fritz
Cyclooxygenase-2 Expression in Human Colorectal Cancer Is Unrelated to Overall Patient Survival
Clin. Cancer Res., July 1, 2005; 11(13): 4754 - 4760.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Brown and R. N. DuBois
COX-2: A Molecular Target for Colorectal Cancer Prevention
J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Kawamori, T. Kitamura, K. Watanabe, N. Uchiya, T. Maruyama, S. Narumiya, T. Sugimura, and K. Wakabayashi
Prostaglandin E receptor subtype EP1 deficiency inhibits colon cancer development
Carcinogenesis, February 1, 2005; 26(2): 353 - 357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. J. Dannenberg, S. M. Lippman, J. R. Mann, K. Subbaramaiah, and R. N. DuBois
Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
J. Clin. Oncol., January 10, 2005; 23(2): 254 - 266.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. T. Hawk and B. Levin
Colorectal Cancer Prevention
J. Clin. Oncol., January 10, 2005; 23(2): 378 - 391.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. Garcea, D. P. Berry, D. J.L. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher
Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 120 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. T. Nam, K.-B. Hahm, S.-Y. Oh, M. Yeo, S.-U. Han, B. Ahn, Y.-B. Kim, J. S. Kang, D. D. Jang, K.-H. Yang, et al.
The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter pylori-Associated Gastric Cancer Development in a Mouse Model
Clin. Cancer Res., December 1, 2004; 10(23): 8105 - 8113.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. D. Basu, L. B. Pathangey, T. L. Tinder, M. LaGioia, S. J. Gendler, and P. Mukherjee
Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer
Mol. Cancer Res., November 1, 2004; 2(11): 632 - 642.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. E. Moran, D. H. Hunt, S. H. Javid, M. Redston, A. M. Carothers, and M. M. Bertagnolli
Apc Deficiency Is Associated with Increased Egfr Activity in the Intestinal Enterocytes and Adenomas of C57BL/6J-Min/+ Mice
J. Biol. Chem., October 8, 2004; 279(41): 43261 - 43272.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
D. L. Simmons, R. M. Botting, and T. Hla
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Pharmacol. Rev., September 1, 2004; 56(3): 387 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. A. Adegboyega, O. Ololade, J. Saada, R. Mifflin, J. F. Di Mari, and D. W. Powell
Subepithelial Myofibroblasts Express Cyclooxygenase-2 in Colorectal Tubular Adenomas
Clin. Cancer Res., September 1, 2004; 10(17): 5870 - 5879.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Shishodia, D. Koul, and B. B. Aggarwal
Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates TNF-Induced NF-{kappa}B Activation through Inhibition of Activation of I{kappa}B{alpha} Kinase and Akt in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of COX-2 Synthesis
J. Immunol., August 1, 2004; 173(3): 2011 - 2022.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Hull, S. C.W. Ko, and G. Hawcroft
Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer?
Mol. Cancer Ther., August 1, 2004; 3(8): 1031 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Shishodia and B. B. Aggarwal
Cyclooxygenase (COX)-2 Inhibitor Celecoxib Abrogates Activation of Cigarette Smoke-Induced Nuclear Factor (NF)-{kappa}B by Suppressing Activation of I-{kappa}B {alpha} Kinase in Human Non-Small Cell Lung Carcinoma: Correlation with Suppression of Cyclin D1, COX-2, and Matrix Metalloproteinase-9
Cancer Res., July 15, 2004; 64(14): 5004 - 5012.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. I. Abdalla, P. Lao-Sirieix, M. R. Novelli, L. B. Lovat, I. R. Sanderson, and R. C. Fitzgerald
Gastrin-Induced Cyclooxygenase-2 Expression in Barrett's Carcinogenesis
Clin. Cancer Res., July 15, 2004; 10(14): 4784 - 4792.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. C. H. Hardwick, M. van Santen, G. R. van den Brink, S. J. H. van Deventer, and M. P. Peppelenbosch
DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1
Carcinogenesis, July 1, 2004; 25(7): 1293 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman
Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs
Clin. Cancer Res., June 1, 2004; 10(11): 3908 - 3918.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
H. E. Zeytin, A. C. Patel, C. J. Rogers, D. Canter, S. D. Hursting, J. Schlom, and J. W. Greiner
Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor Immunity and Long-Term Survival in CEA.Tg/MIN Mice
Cancer Res., May 15, 2004; 64(10): 3668 - 3678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Gupta, V. M. Adhami, M. Subbarayan, G. T. MacLennan, J. S. Lewin, U. O. Hafeli, P. Fu, and H. Mukhtar
Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model
Cancer Res., May 1, 2004; 64(9): 3334 - 3343.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-S. Chun, S.-H. Kim, Y.-S. Song, and Y.-J. Surh
Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin
Carcinogenesis, May 1, 2004; 25(5): 713 - 722.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Xiao, B. T. Luke, G. Izmirlian, A. Umar, P. M. Lynch, R. K. S. Phillips, S. Patterson, T. P. Conrads, T. D. Veenstra, P. Greenwald, et al.
Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors
Cancer Res., April 15, 2004; 64(8): 2904 - 2909.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Wei, L. Wang, Y. He, H. Q. Xiong, J. L. Abbruzzese, and K. Xie
Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity
Cancer Res., March 15, 2004; 64(6): 2030 - 2038.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. W. Davis, B. S. Zweifel, J. M. O'Neal, D. M. Heuvelman, A. L. Abegg, T. O. Hendrich, and J. L. Masferrer
Inhibition of Cyclooxygenase-2 by Celecoxib Reverses Tumor-Induced Wasting
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 929 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Wu, J. Leng, C. Han, and A. J. Demetris
The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells
Mol. Cancer Ther., March 1, 2004; 3(3): 299 - 307.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
F. G. Bottone Jr, J. M. Martinez, B. Alston-Mills, and T. E. Eling
Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells
Carcinogenesis, March 1, 2004; 25(3): 349 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. W. Chang, D. H. Kim, D. P. Kowalski, J. A. Burleson, Y. H. Son, L. D. Wilson, and B. G. Haffty
Prognostic Significance of Cyclooxygenase-2 in Oropharyngeal Squamous Cell Carcinoma
Clin. Cancer Res., March 1, 2004; 10(5): 1678 - 1684.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Han, J. Leng, A. J. Demetris, and T. Wu
Cyclooxygenase-2 Promotes Human Cholangiocarcinoma Growth: Evidence for Cyclooxygenase-2-Independent Mechanism in Celecoxib-Mediated Induction of p21waf1/cip1 and p27kip1 and Cell Cycle Arrest
Cancer Res., February 15, 2004; 64(4): 1369 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. V. Swamy, I. Cooma, J. M.R. Patlolla, B. Simi, B. S. Reddy, and C. V. Rao
Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment
Mol. Cancer Ther., February 1, 2004; 3(2): 215 - 221.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
C. C. Ziegler, L. Rainwater, J. Whelan, and M. F. McEntee
Dietary Resveratrol Does Not Affect Intestinal Tumorigenesis in ApcMin/+ Mice
J. Nutr., January 1, 2004; 134(1): 5 - 10.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Kazanov, H. Dvory-Sobol, M. Pick, E. Liberman, L. Strier, E. Choen-Noyman, V. Deutsch, T. Kunik, and N. Arber
Celecoxib But Not Rofecoxib Inhibits the Growth of Transformed Cells in Vitro
Clin. Cancer Res., January 1, 2004; 10(1): 267 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. M. Ward and D. E. Devor-Henneman
Mouse Models of Human Familial Cancer Syndromes
Toxicol Pathol, January 1, 2004; 32(1_suppl): 90 - 98.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
S. H. Diks, J. C. Hardwick, R. M. Diab, M. M. van Santen, H. H. Versteeg, S. J. H. van Deventer, D. J. Richel, and M. P. Peppelenbosch
Activation of the Canonical {beta}-Catenin Pathway by Histamine
J. Biol. Chem., December 26, 2003; 278(52): 52491 - 52496.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
N. F. Paoni, M. W. Feldman, L. S. Gutierrez, V. A. Ploplis, and F. J. Castellino
Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/+ mouse
Physiol Genomics, November 11, 2003; 15(3): 228 - 235.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. M Herendeen and C. Lindley
Use of NSAIDs for the Chemoprevention of Colorectal Cancer
Ann. Pharmacother., November 1, 2003; 37(11): 1664 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Higuchi, T. Iwama, K. Yoshinaga, M. Toyooka, M. M. Taketo, and K. Sugihara
A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhibitor, on Rectal Polyps in Familial Adenomatous Polyposis Patients
Clin. Cancer Res., October 15, 2003; 9(13): 4756 - 4760.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Choy and L. Milas
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
J Natl Cancer Inst, October 1, 2003; 95(19): 1440 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Ferrandina, F. O. Ranelletti, F. Legge, L. Lauriola, V. Salutari, M. Gessi, A. C. Testa, U. Werner, P. Navarra, G. Tringali, et al.
Celecoxib Modulates the Expression of Cyclooxygenase-2, Ki67, Apoptosis-Related Marker, and Microvessel Density in Human Cervical Cancer: A Pilot Study
Clin. Cancer Res., October 1, 2003; 9(12): 4324 - 4331.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Takeda, M. Sonoshita, H. Oshima, K.-i. Sugihara, P. C. Chulada, R. Langenbach, M. Oshima, and M. M. Taketo
Cooperation of Cyclooxygenase 1 and Cyclooxygenase 2 in Intestinal Polyposis
Cancer Res., August 15, 2003; 63(16): 4872 - 4877.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. W. J. de Leng, A. M. Westerman, M. A. J. Weterman, F. W. M. de Rooij, H. v. Dekken, A. F. P. M. de Goeij, S. B. Gruber,